The Korea Bio Association announced on the 7th that it will host the '5th Global IR @JPM 2025' at the Nasdaq Entrepreneurial Center in San Francisco, USA, on the 14th (local time). This event will be held during the JP Morgan Healthcare Conference (JPM), the world's largest healthcare investment conference, co-hosted by global law firm Sidley Austin LLP and the biotech media outlet BioCentury, with sponsorship from Nasdaq, the Ministry of Trade, Industry and Energy, and the Biocom California. Now in its fifth year, Global IR @JPM aims to discover promising biotechnology corporations with excellent technologies to enhance investment attraction and promote sustainable growth. The event plans to showcase corporate value through IR pitching in front of domestic and international professional investors and stakeholders, while also providing business networking opportunities with global investment partners to facilitate future collaborations.
Medytox announced on the 7th that it has signed a business promotion agreement with biotechnology startups Mimetics and Excellence selected through the '2024 Seoul Biohub-Medytox Open Innovation Program' and conducted an orientation. Key representatives from Medytox, Seoul Biohub, Seoul, the accelerator BIEX Plant, and the selected startups Mimetics and Excellence attended the event, where an agreement on the open innovation program was signed among the parties. Medytox will provide two promising startups selected from the open innovation program with entry rights to the Seoul Biohub, joint research and product development opportunities through specialized programs based on step-by-step selections, and investment attraction opportunities through Medytox Venture Investment.
Hallym University Medical Center announced on the 7th that Hallym University Sacred Heart Hospital, Hallym University Gangnam Sacred Heart Hospital, and Hallym University Dongtan Sacred Heart Hospital received the highest grade, A grade, in the Ministry of Health and Welfare's '2024 Emergency Medical Institution Evaluation'. In particular, Hallym University Sacred Heart Hospital ranked 1st in Gyeonggi Province and 2nd nationwide, achieving the highest grade for six consecutive years, while Hallym University Dongtan Sacred Heart Hospital maintained its reputation by keeping the highest grade for 12 consecutive years. The Ministry evaluates emergency medical institutions nationwide annually to improve the quality of emergency medical services. This evaluation considered the operational performance of a total of 408 emergency medical institutions, including regional emergency medical centers and local emergency medical institutions, from July 2023 to June 2024, based on 27 detailed indicators across seven areas: essentiality, safety, effectiveness, timeliness, functionality, publicness, and monitoring.
SillaJen announced on the 7th that it has signed a clinical drug support agreement with Swiss pharmaceutical company BeiGene. Under this agreement, BeiGene will provide SillaJen with the PD-1 inhibitor Tislelizumab to conduct combination clinical trials with BAL0891, which is currently being developed as a solid tumor treatment in the U.S. and South Korea. SillaJen's BAL0891 is a mitotic checkpoint inhibitor introduced from Swiss Basel, and it is a first-in-class drug. Currently, a phase 1 trial is underway to evaluate safety and maximum tolerated dose in patients with solid tumors, and plans for additional research in patients with acute myeloid leukemia (AML) are in place. Tislelizumab is a monoclonal antibody with high affinity and specificity for PD-1, being developed as a treatment for various cancers.
Syntekabio announced on the 7th that it has obtained platinum certification for the ABS Center's eco-friendly green data center, which is based on the world's only end-to-end AI drug development platform. The guidelines for building green data centers are national standards established to enhance the energy efficiency of data centers and promote environmentally friendly operations. The platinum rating, which Syntekabio has obtained, is the highest level of this standard and requires meeting criteria for sustainability and technological innovation. It is regarded as an important milestone that strengthens international competitiveness beyond environmental responsibility, comparable to the internationally recognized LEED platinum rating. Syntekabio's ABS Center maintains an average power usage effectiveness (PUE) of 1.13 during data center operations, achieving both energy savings and economic efficiency. It has maximized cooling efficiency by utilizing patented air circulation technology based on a natural convection heat dissipation method that mimics termite nest structures, which operates independently and utilizes high-efficiency cooling technology without air conditioning, thus creating a sustainable data center model.
Global healthcare corporation InBody announced on the 7th that it will participate in CES 2025, the world's largest electronics and IT exhibition, held in Las Vegas, USA, from the 7th to the 10th (local time). InBody will showcase various products and solutions under the theme 'Experience healthcare innovation directly' and present the future of healthcare technology based on body composition analysis. The booth, designed for hands-on experience, will feature not only InBody but also its subsidiary KOROT, which specializes in blood pressure monitors, and the InBody Founders Academy, sharing visions for medical device innovation and next-generation talent cultivation.
Metaphines, a biotech venture specializing in metabolism-based cancer treatment and palliation therapies, announced on the 7th that it has received approval for its clinical phase 2 trial plan for its innovative cancer cachexia treatment 'ASCA101CC' from the Ministry of Food and Drug Safety. Cancer cachexia is known to be a common cancer-related complication experienced by about 80% of patients with advanced cancer, accounting for approximately 20% of the total cancer mortality causes. It occurs due to several factors, including appetite suppression, imbalance in energy metabolism and muscle homeostasis, and loss of muscle mass due to inflammatory factors, and it is considered an incurable disease with no fundamentally treatable drugs available so far. ASCA101CC is a multi-modal innovative drug developed to prevent the occurrence and worsening of muscle loss, which is a major symptom of cancer cachexia. Its efficacy and safety have been proven through preclinical and phase 1 trials.
DDH, a dental AI diagnostics solution development corporation, announced on the 7th that it has signed an industry-academia cooperation agreement with the School of Stomatology at Shandong First Medical University in Jinan, China, to establish a curriculum for students of the Stomatology School aimed at learning DDH solutions for the training of next-generation digital dentists. Shandong First Medical University has over 25,000 students and has established two campuses in Jinan and Tai'an, hosting 15 affiliated hospitals, and rapidly developing as a medical university specialized in AI and data. Through this agreement, the Stomatology School of Shandong First Medical University will prioritize the application of the DDH solution curriculum to a digital education room capable of accommodating 200 students simultaneously within the 'Shandong First Medical University Dental Hospital,' which is scheduled to open in September 2025, and will extend this curriculum to ten other dental departments at universities across China.